About The Study: In this study including 4,819 women with benign breast disease (BBD) in the percutaneous biopsy era, overall risk of breast cancer was increased versus the general population (ductal carcinoma in situ and invasive cancer combined), similar to that in historical BBD cohorts. Development and validation of pathologic classifications including both BBD severity and multiplicity may enable improved breast cancer risk stratification.
Authors: Amy C. Degnim, M.D., of the Mayo Clinic in Rochester, Minnesota, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamasurg.2023.6382)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2023.6382?guestAccessKey=ba864639-0fbe-44b2-8169-e985a536a288&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=121323
JAMA Surgery